A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
What is multiple myeloma?
Plasma cells are white blood cells that make antibodies. In multiple myeloma, abnormal plasma cells multiply in the bone marrow, crowd out normal blood cells, and produce a useless antibody fragment, often called M protein or, when only part of it is made, light chains. The consequences explain the symptoms: bone pain and fractures as the cells damage bone, anemia and fatigue as marrow is crowded out, kidney damage from light chains, and high calcium from bone breakdown. Bone pain, especially in the back or ribs, is the most common first sign, and unexplained anemia or kidney problems on routine blood work are often how it is found. It is diagnosed with blood and urine tests for M protein, a bone marrow biopsy, and imaging.
Myeloma is a disease of older adults: most people are at least 65 at diagnosis and fewer than 1 percent are under 35. The lifetime risk is about 1 in 108 for men and 1 in 133 for women, and it is about twice as common in Black Americans as in White Americans. It is not usually inherited, though having a close relative with it raises risk modestly. Treatment now typically starts with four drugs at once, often followed by a stem cell transplant using the patient's own cells and then years of maintenance therapy. When the disease returns, and it usually does, the options include CAR T cell therapy, approved as early as second line since April 2024, bispecific antibodies that connect immune cells to myeloma cells, and newer pills.
Interested in learning more about new multiple myeloma treatments? Read our guide: How New Treatments For Multiple Myeloma Could Impact You
Types of multiple myeloma clinical trials
CAR T cell therapy trials. New CAR T products, including "off the shelf" versions made from donor cells and gene edited with CRISPR, and trials moving CAR T earlier, even to first treatment.
Bispecific antibody trials. Antibodies that grab a myeloma cell with one arm and a T cell with the other, tested in new combinations and compared with standard regimens in Phase 3.
New pills. Next generation immune modulating drugs and protein degraders, tested with dexamethasone in relapsed disease.
First line and transplant trials. Which four drug combination works best, whether transplant is still needed for everyone, and how long maintenance should last.
In vivo gene therapy. Early trials that engineer immune cells inside the body rather than in a lab.
Supportive care. Exercise and lifestyle programs, bone protection, and infection prevention during treatment.
New to research? Read how clinical trials for cancer work.
Who can participate in multiple myeloma clinical trials?
Trials sort people by where they are in treatment. Newly diagnosed studies enroll people before or shortly after their first therapy and often split by whether they are candidates for transplant. Relapsed trials specify how many prior lines of treatment you must have had, often one to three, and whether you must be refractory to particular drug classes. CAR T and bispecific trials require adequate organ function and often a specific marker such as BCMA or GPRC5D on the myeloma cells. Smoldering myeloma, the early stage without symptoms, has its own prevention trials. Eligibility always varies by study.
Is multiple myeloma curable?
It is still considered incurable, but it is increasingly a long term disease. Many people live for years through several lines of treatment, and in the first CAR T trial about a third of heavily pretreated people remained free of progression for five years or more without further therapy, which has led some researchers to speak of functional cure.
How multiple myeloma is staged, and why it matters for trials
Smoldering myeloma. Abnormal plasma cells and M protein but no organ damage. Watched, or enrolled in trials testing early treatment.
Active myeloma, stages I to III. Staged by blood markers such as albumin, beta 2 microglobulin, and LDH, plus high risk genetic changes in the myeloma cells. Higher stage and high risk genetics mean more aggressive disease and often a separate set of trials.
Relapsed and refractory. Disease that returned after treatment (relapsed) or stopped responding during it (refractory). Most new drug trials enroll here, defined by the number of prior lines.
Study titles say "newly diagnosed," "transplant eligible," or "relapsed/refractory after 1 to 3 prior lines," and often name a target such as BCMA. Your treatment history is the key that unlocks the right studies.
How to enroll in a multiple myeloma clinical trial
Identify your trial. Use the filters. Titles name the setting and line of treatment; match them to your history.
Select your preferred location. Enter your city or state. CAR T trials run at transplant centers and involve hospital stays; many pill and antibody trials run at community oncology practices too.
Explore study details. Click "Learn More" for prior treatment requirements, marker tests, and the visit schedule.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your stage and any high risk genetic results, every treatment you have had in order, and whether you have had a transplant.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.